Isomorphic Labs in talks to raise at ~$50B valuation, IND filing by end of 2026
ns123abc · x · 2026-10-08
Isomorphic Labs, Demis Hassabis's AI drug discovery company, is reportedly in talks for new funding at a $50 billion valuation, with a mission to "solve all disease." The company expects to file its first Investigational New Drug application and begin first-in-human testing by the end of 2026.
Related event: Isomorphic Labs in Talks for Funding at Valuation Up to $50 Billion(6 posts)→
More from Venture
- "Most AI-pilled people are underspending": $100k/month Claude bill sparks debate — ravisparikh · 2026-10-08
- Synthesia revenue grew 94% as 95% of Fortune 100 now uses it — alexvoica · 2026-10-08
- Tian Keyu's world-model startup raises ~$30M at ~$200M valuation, teaching AI its own 200k-symbol language — teortaxesTex · 2026-10-08
- Lossfunk residents hit YC W26 and EF S26, with $175K in Google Cloud credits disbursed — sachdh · 2026-10-08
- Why assume open-weight model providers will stay open forever? — Atlan_ · 2026-10-08
- Hassabis's Isomorphic Labs in talks to raise at ~$50 billion valuation — ns123abc · 2026-10-08